Patent intelligence · US
US 11433097
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
Patent details — US 11433097
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 6, 2022
- Expiration
- Sep 1, 2042
- Applicant
- Iovance Biotherapeutics, Inc.
- Claims
- 23
- CPC classes
- A61K, A61K2239/38, A61K2239/57, A61K35/00
Quick answer
US 11433097 (Methods of using tumor infiltrating lymphocytes in double-refractory melanoma) is held by Iovance Biotherapeutics, Inc.. Status: granted. Granted Sep 6, 2022. Expires Sep 1, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Iovance Biotherapeutics, Inc.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K2239/38, A61K2239/57, A61K35/00, A61K40/11, A61K40/42
More from Iovance Biotherapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12343380
Expansion of TILs utilizing AKT pathways inhibitors
granted -
US 12280140
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
granted -
US 12233075
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
granted -
US 12230378
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
granted -
US 12226434
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 12230379
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
granted -
US 12194061
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 12188048
Restimulation of cryopreserved tumor infiltrating lymphocytes
granted
Frequently asked questions
What is US patent 11433097?
US 11433097 (Methods of using tumor infiltrating lymphocytes in double-refractory melanoma) is held by Iovance Biotherapeutics, Inc.. Status: granted. Granted Sep 6, 2022. Expires Sep 1, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11433097?
Iovance Biotherapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 94 pharmaceutical patents for this assignee.
When does US 11433097 expire?
Our index shows an expiration date of Sep 1, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.